Atlas Trials

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

Clinical trial NCT03552393 · COMPLETED

Trial details

NCT number
NCT03552393
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
AnemiaRenal Insufficiency, Chronic
Start date
2018-08-03
Primary completion
2021-07-19
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.